Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Apr 18, 2019

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2019 Financial Results

SOUTH PLAINFIELD, N.J. , April 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2019 financial results and provide an update on the company's business and outlook on Thursday, May 2, 2019

Mar 04, 2019

PTC Therapeutics to Participate at Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J. , March 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen and Company 39 th Annual Health Care Conference Monday, March 11 th at 11:20 a.m.

Mar 04, 2019

PTC to Expand Product Portfolio in Latin America with WAYLIVRA™

WAYLIVRA, the first and only therapy for the treatment of familial chylomicronemia syndrome (FCS), has received a positive opinion from the CHMP SOUTH PLAINFIELD, N.J. , March 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics ,

Mar 01, 2019

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , March 1, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 25, 2019 it approved non-statutory stock options to purchase an aggregate of 125,000 shares of its common stock to 20 new employees.

Feb 28, 2019

PTC Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides a Corporate Update

SOUTH PLAINFIELD, N.J. , Feb. 28, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2018 . "We are proud to be in the strong position of having a growing revenue base

Feb 25, 2019

PTC Therapeutics Announces Partial Exercise of Underwriter's Option to Purchase Additional Shares

SOUTH PLAINFIELD, N.J. , Feb. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the sole underwriter of its previously announced public offering of 6,720,000 shares of its common stock, which closed on January 25, 2019 , has partially exercised its option to

Feb 14, 2019

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2018 Financial Results

SOUTH PLAINFIELD, N.J. , Feb. 14, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2018 financial results and provide an update on the company's business and outlook on

Feb 13, 2019

PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy

- STRIVE Awards have Supported Over 20 Projects in 15 Countries- -Grant Proposals from Nonprofit Patient Advocacy Organizations Due April 30- SOUTH PLAINFIELD, N.J. , Feb. 13, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the fifth annual STRIVE grant

Jan 31, 2019

PTC Therapeutics Launches New Program to Support Research Projects in Rare, Genetic Disorders

- $500,000 funding to improve Duchenne muscular dystrophy diagnosis and screening in 2019 - SOUTH PLAINFIELD, N.J. , Jan. 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today launched PRIORITY, an annual funding program for innovative research.

Jan 25, 2019

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , Jan. 25, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on January 22, 2019 it approved non-statutory stock options to purchase an aggregate of 170,050 shares of its common stock to 24 new employees.

Pagination

First page
Previous page
…
Page 23
Page 24
Current page 25
Page 26
Page 27
…
Next page
Last page